Squarepoint Ops LLC Has $2.77 Million Stock Holdings in CareDx, Inc. $CDNA

by · The Markets Daily

Squarepoint Ops LLC trimmed its position in shares of CareDx, Inc. (NASDAQ:CDNA – Free Report) by 34.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 141,683 shares of the company’s stock after selling 74,120 shares during the period. Squarepoint Ops LLC owned approximately 0.27% of CareDx worth $2,768,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC raised its stake in shares of CareDx by 6.1% in the first quarter. Acadian Asset Management LLC now owns 359,303 shares of the company’s stock valued at $6,373,000 after purchasing an additional 20,806 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in CareDx by 67.8% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 53,527 shares of the company’s stock valued at $950,000 after buying an additional 21,627 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of CareDx in the 2nd quarter valued at $352,000. Envestnet Asset Management Inc. raised its stake in shares of CareDx by 17.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company’s stock valued at $439,000 after buying an additional 3,389 shares in the last quarter. Finally, Hood River Capital Management LLC lifted its holdings in shares of CareDx by 11.5% during the 2nd quarter. Hood River Capital Management LLC now owns 1,765,981 shares of the company’s stock worth $34,507,000 after acquiring an additional 182,025 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday. Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a report on Monday. William Blair initiated coverage on CareDx in a research note on Tuesday, August 26th. They issued a “market perform” rating on the stock. Finally, Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $26.67.

View Our Latest Analysis on CareDx

CareDx Price Performance

NASDAQ CDNA opened at $19.49 on Thursday. The stock’s 50 day simple moving average is $16.50 and its 200 day simple moving average is $15.80. CareDx, Inc. has a one year low of $10.96 and a one year high of $25.95. The firm has a market cap of $1.00 billion, a PE ratio of 16.38 and a beta of 2.54.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.15. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The firm had revenue of $100.06 million during the quarter, compared to the consensus estimate of $95.25 million. During the same quarter in the previous year, the company posted ($0.14) EPS. The business’s revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, equities analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current year.

CareDx Company Profile

(Free Report)

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Recommended Stories